Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure – A multicenter propensity score matched analysis
Täger, Tobias; Fröhlich, Hanna; Grundtvig, Morten; Seiz, Mirjam; Schellberg, Dieter; Goode, Kevin; Kazmi, Syed; Hole, Torstein; Katus, Hugo A.; Atar, Dan; Cleland, John G.F.; Agewall, Stefan; Clark, Andrew L.; Frankenstein, Lutz
Journal article, Peer reviewed
Accepted version

View/ Open
Date
2019Metadata
Show full item recordCollections
Abstract
Background
Loop diuretics are given to the majority of patients with chronic heart failure (HF). Whether the different pharmacological properties of the three guideline-recommended loop diuretics result in differential effects on survival is unknown.
Methods
6293 patients with chronic HF using either bumetanide, furosemide or torasemide were identified in three European HF registries. Patients were individually matched on both the respective propensity scores for receipt of the individual drug and dose-equivalents thereof.
Results
During a follow-up of 35,038 patient-years, 652 (53.7%), 2179 (51.9%), and 268 (30.4%) patients died amongst those prescribed bumetanide, furosemide, and torasemide, respectively. In univariable analyses of the general sample, bumetanide and furosemide were both associated with higher mortality as compared with torasemide treatment (HR 1.50, 95% CI 1.31–1.73, p < 0.001, and HR 1.34, CI 1.18–1.52, p < 0.001, respectively). Mortality was higher in bumetanide users when compared to furosemide users (HR 1.11, 95% CI 1.02–1.20, p = 0.01). However, there was no significant association between loop diuretic choice and all-cause mortality in any of the matched samples (bumetanide vs. furosemide, HR 1.03, 95% CI 0.93–1.14, p = 0.53; bumetanide vs. torasemide, HR 0.98, 95% CI 0.78–1.24, p = 0.89; furosemide vs. torasemide, HR 1.02, 95% CI 0.84–1.24, p = 0.82). The results were confirmed in subgroup analyses with respect to age, sex, left ventricular ejection fraction, NYHA functional class, cause of HF, rhythm, and systolic blood pressure.
Conclusions
In patients with HF, mortality is not affected by the choice of individual loop diuretics.